Tag Archives: ALXN

Top 10 Low Price Stocks To Invest In 2019

Retirement investors want sure things. There isn’t enough time to make up for stocks that just fall into the ground, never to return. So considering how awful energy has been for the past couple of years, it’s probably surprising to see “energy stocks” and “retirement” mentioned in the same vicinity.

Sustained low oil and natural gas prices have negatively impacted energy stocks. OK, that’s putting it mildly. Low prices have outright strangled some companies right out of business, and has made life miserable for the vast majority of the sector.

See Also: Earn 5% to 11% With Master Limited Partnerships

And considering many retirement investors were sucked in by the plentiful dividends in the energy sector, they know the pain. And they’re probably not too forgiving.

Top 10 Low Price Stocks To Invest In 2019: MDU Resources Group, Inc.(MDU)

Advisors’ Opinion:

  • [By Shane Hupp]

    MDU Resources Group (NYSE: MDU) and Zenyatta Ventures (OTCMKTS:ZENYF) are both utilities companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

  • [By Logan Wallace]

    Forsta AP Fonden trimmed its holdings in MDU Resources Group Inc (NYSE:MDU) by 13.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 64,700 shares of the utilities provider’s stock after selling 10,300 shares during the period. Forsta AP Fonden’s holdings in MDU Resources Group were worth $1,856,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Royal London Asset Management Ltd. bought a new position in MDU Resources Group Inc (NYSE:MDU) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 76,679 shares of the utilities provider’s stock, valued at approximately $2,199,000.

Top 10 Low Price Stocks To Invest In 2019: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Century Aluminum (CENX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Century Aluminum (CENX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Jon C. Ogg]

    Century Aluminum Co. (NASDAQ: CENX) was down 13.3% at $10.30, and it now has a new 52-week range of $10.13 to $24.77, with that low being put in on the same day.

Top 10 Low Price Stocks To Invest In 2019: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Federated Investors Inc. PA reduced its stake in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 86.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,571 shares of the biopharmaceutical company’s stock after selling 167,443 shares during the quarter. Federated Investors Inc. PA’s holdings in Alexion Pharmaceuticals were worth $2,960,000 at the end of the most recent quarter.

  • [By Chris Lange]

    Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest dropped to 4.37 million shares from the previous level of 5.01 million. Shares were trading at $116.70 in a 52-week range of $102.10 to $149.34.

  • [By Chris Lange]

    The Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) second-quarter report is scheduled for Thursday before the opening bell. The consensus forecast is $1.70 in EPS on $977.89 million in revenue. Shares ended the week at $135.27 apiece. The consensus price target is $158.89, and the 52-week range is $102.10 to $149.34.

  • [By Shane Hupp]

    Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) gapped up before the market opened on Tuesday after Stifel Nicolaus raised their price target on the stock from $130.00 to $136.00. The stock had previously closed at $127.35, but opened at $128.69. Stifel Nicolaus currently has a hold rating on the stock. Alexion Pharmaceuticals shares last traded at $128.94, with a volume of 50491 shares.

Top 10 Low Price Stocks To Invest In 2019: Ringcentral, Inc.(RNG)

Advisors’ Opinion:

  • [By Ethan Ryder]

    RingCentral Inc (NYSE:RNG) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $91.15 and last traded at $90.75, with a volume of 25952 shares changing hands. The stock had previously closed at $88.65.

  • [By Anders Bylund]

    RingCentral (NYSE:RNG) led the way with a 26.3% surge, followed by 8×8 (NYSE:EGHT) at 13.8% and Vonage Holdings (NYSE:VG) scoring a 10.7% gain. All of these one-month returns crushed the broader market, as the S&P 500 benchmark notched just a 3% gain last month.

  • [By Rick Munarriz]

    One of last week’s biggest gainers was RingCentral (NYSE:RNG), moving 10% higher after posting another quarter of better-than-expected financial results. The strong report sent the shares to fresh all-time highs. The stock is now nearly a seven-bagger since going public at $13 five years ago. 

  • [By Shane Hupp]

    Shares of RingCentral (NYSE:RNG) were up 2.9% during trading on Friday after SunTrust Banks raised their price target on the stock to $80.00. SunTrust Banks currently has a buy rating on the stock. RingCentral traded as high as $81.20 and last traded at $74.55. Approximately 19,219 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 485,528 shares. The stock had previously closed at $76.80.

  • [By Max Byerly]

    RingCentral Inc (NYSE:RNG) COO David Sipes sold 9,300 shares of RingCentral stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $77.71, for a total transaction of $722,703.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Top 10 Low Price Stocks To Invest In 2019: Foot Locker, Inc.(FL)

Advisors’ Opinion:

  • [By JJ Kinahan]

    With retail earnings season pretty much over, one key takeaway is how many so-called “brick-and-mortar” stores have found ways to keep customers coming in the doors rather than simply pointing and clicking. Many retailers had very good same-store sales, and what that shows is the traffic is still there for them. The challenge for retailers now is converting traffic to buyers, and retailers appear to have gotten much more creative and much better at helping their clients. About 70 percent of specialty retailers—which are smaller, niche-type stores—beat Wall Street’s forecasts for the quarter, according to Bloomberg research, and the S&P 500 Specialty Retail Index has actually outperformed the S&P 500 Internet Index since mid-March. Strong results reported by specialty retailers like Foot Locker, Inc. (NYSE: FL) and Tiffany & Co. (NYSE: TIF) last week have helped buttress the sector.

  • [By Ethan Ryder]

    Metropolitan Life Insurance Co. NY decreased its position in shares of Foot Locker, Inc. (NYSE:FL) by 7.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 17,852 shares of the athletic footwear retailer’s stock after selling 1,404 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Foot Locker were worth $940,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Stephan Byrd]

    BNP Paribas Arbitrage SA lowered its holdings in Foot Locker (NYSE:FL) by 18.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,165 shares of the athletic footwear retailer’s stock after selling 34,833 shares during the period. BNP Paribas Arbitrage SA owned approximately 0.13% of Foot Locker worth $7,203,000 as of its most recent SEC filing.

Top 10 Low Price Stocks To Invest In 2019: Dicerna Pharmaceuticals, Inc.(DRNA)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Agilent Technologies, Inc. (NYSE: A) is estimated to post quarterly earnings at $0.64 per share on revenue of $1.21 billion.
    Vipshop Holdings Limited (NYSE: VIPS) is expected to post quarterly earnings at $0.18 per share on revenue of $3.10 billion.
    Rexnord Corporation (NYSE: RXN) is projected to post quarterly earnings at $0.39 per share on revenue of $551.94 million.
    Invitation Homes Inc. (NYSE: INVH) is estimated to post quarterly earnings at $0.03 per share on revenue of $423.13 million.
    Switch, Inc. (NYSE: SWCH) is expected to post quarterly earnings at $0.05 per share on revenue of $99.83 million.
    Itron, Inc. (NASDAQ: ITRI) is projected to post quarterly earnings at $0.13 per share on revenue of $579.85 million.
    Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) is expected to post quarterly earnings at $0.44 per share on revenue of $119.06 million.
    Amyris, Inc. (NASDAQ: AMRS) is estimated to post quarterly earnings at $0.07 per share on revenue of $68.14 million.
    Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) is projected to post quarterly loss at $0.38 per share on revenue of $1.87 million.
    VOXX International Corporation (NASDAQ: VOXX) is expected to post quarterly earnings at $0.05 per share on revenue of $130.00 million.
    Phoenix New Media Limited (NYSE: FENG) is estimated to post quarterly loss at $0.12 per share on revenue of $45.38 million.
    Restoration Robotics, Inc. (NASDAQ: HAIR) is projected to post quarterly loss at $0.17 per share on revenue of $5.93 million.
    YogaWorks, Inc. (NASDAQ: YOGA) is estimated to post quarterly loss at $0.22 per share on revenue of

  • [By Stephan Byrd]

    Spark Investment Management LLC reduced its position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 30.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,200 shares of the biopharmaceutical company’s stock after selling 44,800 shares during the period. Spark Investment Management LLC owned about 0.19% of Dicerna Pharmaceuticals worth $1,227,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Dicerna Pharmaceuticals (NASDAQ:DRNA) had its target price upped by research analysts at B. Riley from $10.00 to $13.50 in a research note issued on Monday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. B. Riley’s price target indicates a potential downside of 20.26% from the company’s current price.

  • [By Shane Hupp]

    Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) insider James B. Weissman sold 2,301 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $17.50, for a total value of $40,267.50. Following the sale, the insider now owns 26,781 shares in the company, valued at approximately $468,667.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Top 10 Low Price Stocks To Invest In 2019: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Tower Semiconductor Ltd. (NASDAQ: TSEM) fell 16.1 percent to $23.10 in pre-market trading after reporting downbeat quarterly results.
    Integrated Media Technology Limited (NASDAQ: IMTE) fell 13 percent to $18.00 in pre-market trading after declining 37.37 percent on Friday.
    Ability Inc. (NASDAQ: ABIL) shares fell 7.1 percent to $2.61 in pre-market trading.
    International Flavors & Fragrances Inc. (NYSE: IFF) shares fell 6.4 percent to $133.00 in pre-market trading. International Flavors & Fragrances reported upbeat earnings for its first quarter and agreed to acquire Frutarom for $7.1 billion.
    BHP Billiton Limited (NYSE: BHP) fell 6.8 percent to $45.00 in pre-market trading.
    Sibanye Gold Limited (NYSE: SBGL) fell 6.4 percent to $3.23 in pre-market trading after dropping 2.27 percent on Friday.
    Spark Therapeutics, Inc. (NASDAQ: ONCE) fell 5.9 percent to $66.52 in pre-market trading after declining 1.15 percent on Friday.
    DENTSPLY SIRONA Inc. (NASDAQ: XRAY) shares fell 4 percent to $48.00 in pre-market trading. DENTSPLY SIRONA reported Q1 adjusted earnings of $0.45 per share on sales of $956.1 million. The company updated its 2018 adjusted earnings guidance to $2.55 to 2.65 per share

  • [By Logan Wallace]

    Spark Therapeutics (NASDAQ:ONCE) has been given a $103.00 target price by equities research analysts at Cantor Fitzgerald in a report released on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 111.85% from the stock’s current price.

  • [By Ethan Ryder]

    FIL Ltd cut its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 9.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,134 shares of the biotechnology company’s stock after selling 8,084 shares during the period. FIL Ltd owned approximately 0.21% of Spark Therapeutics worth $5,270,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Low Price Stocks To Invest In 2019: Avnet, Inc.(AVT)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Avnet (AVT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Robeco Institutional Asset Management B.V. raised its holdings in Avnet (NYSE:AVT) by 36.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,627 shares of the technology company’s stock after purchasing an additional 17,261 shares during the period. Robeco Institutional Asset Management B.V. owned 0.05% of Avnet worth $2,772,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Avnet (AVT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    TLP Group LLC bought a new position in Avnet (NYSE:AVT) in the first quarter, HoldingsChannel reports. The fund bought 10,320 shares of the technology company’s stock, valued at approximately $431,000.

  • [By Stephan Byrd]

    DekaBank Deutsche Girozentrale raised its stake in Avnet (NYSE:AVT) by 763.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,310 shares of the technology company’s stock after purchasing an additional 63,936 shares during the period. DekaBank Deutsche Girozentrale owned about 0.06% of Avnet worth $3,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Top 10 Low Price Stocks To Invest In 2019: Samsung Electronics Co. Ltd. (SSNLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Cirrus announced that the first product containing its new ANC chip last spring. In the most recent conference call, the company mentioned that it was in a new headset with a major OEM. A search looking for design breakdowns for Cirrus revealed two new products with Cirrus ANC inside. ABI Research reported finding the Cirrus ANC chip, 47L50C, inside replacing a chip from “Maxim MAX98730” The rest of the parts in the Studio 3 were the same as its predecessor Solo3. Beats increased the price on the Studio 3 by $50. ABI also found the 47L50C inside one of the new Samsung (OTC:SSNLF) products adding this statement, “Cirrus seems to be doing quite well in the ANC (Active noise cancellation) market as this is the second win we have seen (47L51b found in the Samsung ANC earbuds) in blooming ANC market.” There appear to be two new sets of earbuds from Samsung, a wired and a wireless. It is unclear to us which or perhaps both could have the new Cirrus chip inside. We know of at least three major brands with Cirrus ANC inside. The list continues to grow. We note we have yet to find a product with both parts, mics and codec. The four freshly washed E9s (ABBA) have eased the consist across the aligned switch onto the main with the semaphore straight up green-lighting the ANC Express and for those aboard, sensing the QUIET of the early morn.

  • [By ]

    Okay, let’s not devolve into an exciting technical discussion, other than to say there are two primary choices for the NAND offerings in production. Samsung (OTC:SSNLF), SK Hynix (OTC:HXSCF), Toshiba (OTCPK:TOSBF), and Western Digital (WDC) all developed their 3DNand using “Charge Trap” technology. But the Intel Micron Flash Technologies partners Intel (INTC) and Micron Technology (MU) selected “Floating Gate” and made sure to tell us how right they were and how wrong the other camp was.

  • [By ]

    ADT is taking aim at the resident-monitored market by partnering with technology provider Samsung (OTC:SSNLF) for a line of a do-it-yourself (DIY) home-security products. The products are supported by ADT’s monitoring service, and consumers can sign up for month-to-month plans. ADT will also integrate Ring Doorbells with its monitoring services if customers desire.

  • [By Jamal Carnette, CFA]

    While the news centered on Apple’s position slip, Samsung (NASDAQOTH:SSNLF) fared the worst of all major smartphone manufacturers when you drill further into the numbers. Smartphone shipments for Samsung fell 10.4% on a year-on-year basis, with Chinese competitors Huawei and Xiaomi appearing to take the lost market share. 

  • [By Anders Bylund]

    That would be South Korean memory giants Samsung (NASDAQOTH:SSNLF) and SK Hynix. Samsung controls nearly half the global market for DRAM chips while Hynix and Micron split the other half down the middle. Other chip manufacturers play a forgettable role in the total market. The NAND sector is a bit more diversified thanks to the presence of Western Digital (NASDAQ:WDC) and its all-important SanDisk subsidiary but Micron is one of the largest suppliers in this segment as well.

Top 10 Low Price Stocks To Invest In 2019: NewMarket Corporation(NEU)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on NewMarket (NEU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Here are some of the media stories that may have effected Accern’s rankings:

    Get NewMarket alerts:

    NewMarket’s (NEU) CEO Teddy Gottwald on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com) NEU Crosses Below Key Moving Average Level (nasdaq.com) NewMarket misses by $1.15, misses on revenue (seekingalpha.com) NewMarket Corporation Reports Second Quarter and First Half 2018 Results (finance.yahoo.com) NewMarket: 2Q Earnings Snapshot (finance.yahoo.com)

    A number of equities research analysts have weighed in on NEU shares. TheStreet raised NewMarket from a “c” rating to a “b-” rating in a research report on Wednesday, April 25th. ValuEngine lowered NewMarket from a “hold” rating to a “sell” rating in a research report on Saturday, June 2nd.

  • [By Stephan Byrd]

    Royce & Associates LP increased its position in shares of NewMarket Co. (NYSE:NEU) by 0.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,362 shares of the specialty chemicals company’s stock after purchasing an additional 150 shares during the quarter. Royce & Associates LP owned 0.22% of NewMarket worth $10,663,000 as of its most recent filing with the SEC.

Top 10 Value Stocks To Own Right Now

In this report, we highlight stocks that demonstrate solid growth prospects at a reasonable price (GARP) and provide an update of last month’s report and our January 1 rebalancing note. For older reports, you can visit this link.

Methodology

Our criteria for selecting stocks in these model portfolio strategies, which heavily weight proxies for cash flow growth and ROIC, include the following:

Relative Value Operating Momentum Consensus Estimate Revision Momentum Fundamental Quality

Click to enlargeThe highest ranked stocks are selected for our long model portfolios, and the lowest ranked stocks are selected for our short model portfolios.

Top 10 Value Stocks To Own Right Now: eLong, Inc.(LONG)

Advisors’ Opinion:

  • [By Monica Gerson]

    eLong, Inc. (ADR) (NASDAQ: LONG) is projected to post a quarterly loss at $0.60 per share on revenue of $38.31 million.

    Qunar Cayman Islands Ltd (NASDAQ: QUNR) is expected to post a quarterly loss at $8.89 per share on revenue of $1.11 billion.

Top 10 Value Stocks To Own Right Now: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) jumped to the top of the S&P 500 today after Barclays upgraded the biotech stock to Overweight from Equal Weight citing fewer macro headwinds.

    Getty Images

    Shares of Alexion Pharmaceuticals gained 5.2% to $125.59, while the S&P 500 rose 0.1%.

    Barclays analyst Geoff Meacham and team explain why they upgraded Alexion Pharmaceuticals:

    We are upgrading shares ofAlexion to Overweight and increasing our PT to $155 from $150 on an improved outlook for 2017. Specifically, we see lower FX and fewer macroeconomic risks to the core base business over the next 12 months. We also expect approval of Soliris in refractory gMG by YE17 following a planned regulatory submission in 1Q17, which could add another growth lever in early 2018 at the latest. Our upgrade is not a call on the recent 10-Q delay, which according to our discussions with management has to do with an investigation into sales practices following allegations by a former employee. We also do not anticipate major restatements of historical Soliris sales due to the investigation. Furthermore, this is not a call on Kanuma or the Synageva deal, as we have cut our Kanuma sales in our P&L and reduced its contribution in our NPV valuation. Indeed, we would expect minimal weakness inAlexion shares if the company were to take a write-down on Synageva during 2017, but this is not core to our investment thesis. In sum, our bullishness onAlexion shares is due to: 1) lessened FX and macroeconomic headwinds in 2017, 2) near-term Soliris growth from likely regulatory approval in refractory gMG, and 3) attractive upside potential from current levels as the pipeline including line extensions for Soliris and new assets such as 1210 mature.

    Alexion Pharmaceuticals’ market capitalization rose to $28.2 billion today from $26.8 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

Top 10 Value Stocks To Own Right Now: FormFactor, Inc.(FORM)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggested small cap semiconductor equipment & testing stock FormFactor, Inc (NASDAQ: FORM) as a short term long trade thats a pure small cap play with excellent valuation metrics, in addition to some very attractive chart implications right now:

Top 10 Value Stocks To Own Right Now: Mead Johnson Nutrition Company(MJN)

Advisors’ Opinion:

  • [By Michael Flannelly]

    On Tuesday, JP Morgan analysts upgraded children’s nutrition company Mead Johnson Nutrition (MJN), as they believe the company’s top line growth should be valued more highly than the possible cost headwinds and further Chinese regulations.

    The analysts upgraded MJN from “Neutral” to “Overweight” and see shares reaching $88. This price target suggests a 16% upside to the stock’s Monday closing price of $76.11.

    Mead Johnson Nutrition shares were up 85 cents, or 1.12%, during morning trading on Tuesday. The stock is up 16.71% year-to-date.

  • [By WWW.THESTREET.COM]

    The group agreed to sell its food business to McCormick & Company Inc. (MKC)  last week for $4.2 billion. Reckitt said it would use the sale proceeds to reduce debt, which grew by $21 billion through a pair of financing transactions in March led by Bank of America Merrill Lynch, Deutsche Bank and HSBC in order to fund its $18 billion acquisition of infant nutrition group Mead Johnson (MJN) earlier this year.

Top 10 Value Stocks To Own Right Now: Alliance Data Systems Corporation(ADS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Alliance Data Systems (ADS) soared to the top of the S&P 500 today after beating the Street’s earnings and revenue expectations.

    Getty Images

    Alliance Data Systemsgained 8.3% to $260.62, while the S&P 500 rose 0.8% to 2,355.84.

    Evercore ISI’s David Togut and team argue that Alliance Data Systems is “checking the right boxes.” They explain:

    ADS’ 1Q/17 earnings reinforced our conviction that net charge offs will stabilize at the end of this year, driving accelerating earnings growth in 2018. Card Services surpassed our revenue and EBITDA forecasts fueled by an 80 basis point increase in gross card yield thanks to rising interest rates. Epsilon’s revenue growth accelerated to 7% from a 1% decline in 4Q/16 driven by double digit growth in Automotive, Agency and digital CRM plus an easy comparison. LoyaltyOne revenue and EBITDA fell below our estimates given soft results from AIR MILES, which is adjusting its value proposition after the Ontario Legislature last December eliminated the expiration date on AIR MILES. Overall, ADS remains on track to generate double-digit adjusted EBITDA and EPS gains in 2017, and in 2018 to accelerate EPS growth to the mid-teens given slowing headwinds from delinquencies plus operating leverage from stabilizing net charge-off rates.

    Alliance Data Systems’ market capitalization rose to $14.6 billion today from $13.5 billion yesterday.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Alliance Data Systems Corp. (NYSE: ADS) which traded down 3.9% at $238.00. The stocks 52-week range is $185.02 to $254.94. Volume was 1.6 million versus the daily average of 577,000 shares.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Alliance Data Systems Corp. (NYSE: ADS) which jumped 8.3% to $260.56. The stocks 52-week range is $185.02 to $263.40. Volume was roughly 1.2 million which is above the daily average of around 606,000 shares.

Top 10 Value Stocks To Own Right Now: FuelCell Energy Inc.(FCEL)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (January 12th). At the beginning of December, FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.The Company alsoexpects to take a $3 million charge in fiscal 2017 related to the job cuts.

  • [By Jim Robertson]

    Fuel cell power solutions stock FuelCell Energy Inc (NASDAQ: FCEL)sank 28.13% after pricing an underwritten public offering of (i) 12,000,000 shares of its common stock, (ii) Series C warrants to purchase 12,000,000 shares of its common stock and (iii) Series D warrants to purchase 12,000,000 shares of its common stock, for gross proceeds of approximately $15.4 million at a public offering price of $1.28 per share and accompanying warrants.However, shares are rising by a double digit percentage in Monday premarket trading:

  • [By Peter Graham]

    The Q1 2017 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (March 9th). Last December,FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.

Top 10 Value Stocks To Own Right Now: Burcon Nutrascience Corp(BUR)

Advisors’ Opinion:

  • [By William Romov]

    Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.

    Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
    VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
    FXCM Inc. (Nasdaq: GLBR) $1.12 124%
    Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
    ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
    Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
    Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
    LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
    Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
    Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%

    As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.

Top 10 Value Stocks To Own Right Now: MGE Energy Inc.(MGEE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included California Water Service Group (NYSE: CWT), down 7 percent, and MGE Energy, Inc. (NASDAQ: MGEE), down 6 percent.

Top 10 Value Stocks To Own Right Now: Leading Brands Inc(LBIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.

Top 10 Value Stocks To Own Right Now: TheStreet, Inc.(TST)

Advisors’ Opinion:

  • [By Steven Goldberg]

    Launched in August 2001, Action Alerts PLUS Portfolio has been a centerpiece of the financial advice offered by TheStreet.com. The website belongs to TheStreet, Inc. (TST), a publicly traded company that Cramer co-founded in 1996. PLUS Portfolio subscribers, who pay $15 a month, always get the recommendations before Cramer buys them for the portfolio, the Wharton paper reports. Likewise, subscribers get Cramers picks before he airs them on Mad Money.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

Best Undervalued Stocks To Watch For 2018

Value investing may not be dead after all. After a lousy 2015, in which mutual funds that focus on cheap U.S. stocks of all sizes shed an average of 4.7%, bargain hunters have rebounded impressively. Over the past year, the average value fund earned 10.9%.

See Also: 6 Value Stock Picks in a Pricey Market

Few funds have benefited more from the shift in investor sentiment than TCW Relative Value Mid Cap (TGVNX). TCW lost 12.2% in 2015, trailing the typical fund that focuses on undervalued midsize firms by 6.8 percentage points. But over the past year, it outpaced its typical peer by 5.9 percentage points.

Whether markets are friendly or not, manager Diane Jaffee sticks with her strategy. She starts with stocks with market values of $1 billion to $31 billion. She and her team compare five measures of valuedividend yield and the ratio of price to earnings, sales, cash flow and book value (assets minus liabilities)for each stock with comparable figures for the Russell Midcap index.

Best Undervalued Stocks To Watch For 2018: KLA-Tencor Corporation(KLAC)

Advisors’ Opinion:

  • [By JPMorga]

    KLA-Tencor, which is in the process of being acquired by Lam Research, continues to deliver best-in-class dividends as a result of its solid operational performance and strong free cash flow generation. The company’s current dividend yield is at 3.1%. 

  • [By Laurie Kulikowski]

    We rate KLA-TENCOR CORP as a Hold with a ratings score of C. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company’s strengths can be seen in multiple areas, such as its increase in net income, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. 

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that KLAC’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

     

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income increased by 45.2% when compared to the same quarter one year prior, rising from $72.23 million to $104.90 million.

     

  • [By Jim Cramer]

    The company’s current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Semiconductors & Semiconductor Equipment industry and the overall market, KLA-TENCOR CORP’s return on equity significantly exceeds that of both the industry average and the S&P 500.

     

  • [By Jim Cramer]

    The debt-to-equity ratio is very high at 10.70 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company’s weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.00, which shows the ability to cover short-term cash needs.

     

Best Undervalued Stocks To Watch For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) sunk to the bottom of the S&P 500 today, a drop that is being attributed to revelations on Wednesday night that it had to delay its 10-Q because of a whistle blower investigation into its sales practices.

    Getty Images

    Shares of Alexion Pharmaceuticals tumbled 10% to $$113.62 today, while the S&P 500 dipped 0.1% to 2,164.45.

    After speaking with Alexion CEO Vika Sinha, Citigroup’s Robyn Karnauskas and Mohit Bansal see a buying opportunity. “As we highlighted in our previous note, we cannot envision anything that changes numbers fundamentally and see this weakness as buying opportunity,” they write. They also write that they looked at the companies past financials and saw no red flags, while noting that Soliris, the drug that is causing all the problems, “is sold on named patient basis, therefore, chances of fake sales are very minimal.”

    Alexion Pharmaceuticals market capitalization fell to $25.4 billion today from $28.5 billion yesterday.

Best Undervalued Stocks To Watch For 2018: Covanta Holding Corporation(CVA)

Advisors’ Opinion:

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Both of these stocks are overlooked, undervalued, and cash flow machines. The companies are Ascent Capital Group (ASCMA) and Covanta Holdings (CVA).

Best Clean Energy Stocks For 2018

What happened

Shares ofBunge Ltd.(NYSE:BG)rose 10% on Wednesday after the agribusiness and food company released strong fourth-quarter 2016 results.

So what

Quarterly revenue grew 8.6% year over year, to $12.1 billion, and translated to 14.1% growth in adjusted earnings per share, to $1.70. Analysts, on average, were only expecting Bunge to report revenue of $11.4 billion and adjusted earnings of $1.57 per share.

IMAGE SOURCE: Bunge Ltd.

Bunge CEO Soren Schroder elaborated:

Bungehad a solid fourth quarter to end a challenging year. Higher Food & Ingredients and Sugar & Bioenergy results in 2016 reflect our team’s hard work to drive structural improvements to increase the underlying competitiveness of our businesses. Agribusiness faced a very competitive global market environment, but finished strong.

Best Clean Energy Stocks For 2018: ServiceMaster Global Holdings, Inc.(SERV)

Advisors’ Opinion:

  • [By Lee Jackson]

    ServiceMaster Global Holdings Inc. (NYSE: SERV) had its top executive selling shares last week. CEO Robert Gillette sold a total of 343,750 shares at prices that ranged from $36.00 to $36.86 apiece. The total for the sale was about$13 million.The company provides residential and commercial services in the United States, and its shares traded onFriday at $35.50.

Best Clean Energy Stocks For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.

    The shares climbed almost 3.3%, or $3.78, to close at $118.35, compared to the S&P 500, which fell almost 16 points, or 0.7% to end at 2,328.95.

    Its been a rough two years for Alexion. Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices.

    The shares are down more than 3% since the start of 2017.

    Solaris sales will be a focus next week when Alexion reports first quarter financial results. Earlier today, Barclays reiterated an overweight rating on the stock and a $115 price target, but raised its 2018 and 2019 earnings estimates, arguing that rivals are unlikely to significantly challenge either Solaris or the experimental drug ALXN1210.

    …we are increasingly comfortable with the Soliris outlook and now forecast 2021E sales at $4.8B vs. our previous $4.6B, which is +5% ahead of consensus. Weve raised 2017 and 2018 adjusted EPS estimates by $0.05 and $0.10 respectively. Our 5-year revenue CAGR increases by +70 bps to 14.7% while EPS growth has improved by +100 bps to 20.0%, near the top of the peer group.

    Barrons weighed in on Alexion in February, which has been bandied about as a takeout candidate. We have argues

    Earlier this week, Credit Suisse analysts listed Alexion as one of three biotech stocks that will steal the spotlight during earnings season.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) sunk to the bottom of the S&P 500 today, a drop that is being attributed to revelations on Wednesday night that it had to delay its 10-Q because of a whistle blower investigation into its sales practices.

    Getty Images

    Shares of Alexion Pharmaceuticals tumbled 10% to $$113.62 today, while the S&P 500 dipped 0.1% to 2,164.45.

    After speaking with Alexion CEO Vika Sinha, Citigroup’s Robyn Karnauskas and Mohit Bansal see a buying opportunity. “As we highlighted in our previous note, we cannot envision anything that changes numbers fundamentally and see this weakness as buying opportunity,” they write. They also write that they looked at the companies past financials and saw no red flags, while noting that Soliris, the drug that is causing all the problems, “is sold on named patient basis, therefore, chances of fake sales are very minimal.”

    Alexion Pharmaceuticals market capitalization fell to $25.4 billion today from $28.5 billion yesterday.

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Chris Lange]

    Alexion Pharmaceuticals Inc.s (NASDAQ: ALXN) short interest decreased to 4.33 million, compared to the previous level of 4.98 million. Shares closed most recently at $118.83, in a 52-week range of $110.56 to $193.45.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

Best Clean Energy Stocks For 2018: Intuitive Surgical Inc.(ISRG)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, IBM (NYSE:IBM) and Intuitive Surgical (NASDAQ:ISRG) attracted heavy investor interest following their quarterly earnings releases.

  • [By Joseph Hogue]

    Enter Intuitive Surgical (Nasdaq: ISRG) and Da Vinci, a robotic arm that allows surgeons to operate with just a single incision less than an inch in size.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Intuitive Surgical, Inc. (NASDAQ: ISRG) which traded down over 6% at $369.95. The stocks 52-week range is $203.57 to $405.05. Volume was1.9 million versus the daily average of about half a million shares.

  • [By Benzinga News Desk]

    Microsoft (NASDAQ: MSFT) Reports Q4 EPS $0.69 vs. Est. $0.58, Rev. $22.64B vs. Est. $22.14B
    Intuitive Surgical (NASDAQ: ISRG) Reports Q2 GAAP EPS $4.71, Adj. EPS $5.62 vs $4.97 Est., Sales $670.1M vs $540.7M Est.
    Halliburton (NYSE: HAL) Q2 EPS ($0.14) vs ($0.19) est, Revenue $3.84B vs $3.75B est
    Morgan Stanley (NYSE: MS) Q2 EPS $0.75 vs $0.59 est, Revenue $8.9B vs $8.3B est

intraday trading

It's a familiar story to anyone who knows much about financial history…   In the decade or so following the greatest spree of money printing and credit growth in history, we witnessed a tremendous bubble in financial assets.   This bubble saw interest rates on government bonds plummet as bond and stock prices soared.   It saw financial innovations no one had ever thought of before, including new ways to organize capital and banking systems.   It even saw the emergence of new currencies, which soared in value, creating an entirely new class of wealth.   Most people had no idea what to make of all of these new financial innovations. They couldn't believe how much wealth was being created. And in the days following a national holiday, huge crowds of investors stampeded to join in this new financial revolution.   Everyone would soon be rich!

intraday trading: U S Concrete, Inc.(USCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.36 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 10 percent, and Commercial Metals Company (NYSE: CMC), down 4 percent.

  • [By WWW.THESTREET.COM]

    Coming up in tonight’s episode of Mad Money: Cramer interviews Bill Sandbrook, CEO of U.S. Concrete (USCR)  and focuses on opportunities for Xilinx (XLNX) .  Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell 0.73 percent. Meanwhile, top losers in the sector included US Concrete Inc (NASDAQ: USCR), down 8 percent, and Seabridge Gold, Inc. (USA) (NYSE: SA), down 5 percent.

intraday trading: Tele Celular Sul Participacoes S.A.(TSU)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Shenandoah Telecommunications Company (NASDAQ: SHEN), down 3 percent, and TIM Participacoes SA (ADR) (NYSE: TSU) down 2 percent.

intraday trading: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after its audit committee found no need to restate the company’s financials.

    Agence France-Presse/Getty Images

    Alexion Pharmaceuticalsgained 9.5% to $139.18 today, while the S&P 500 dipped 0.1% to 2,269.00.

    Morgan Stanley’sMatthew Harrison and team argue that the audit committees report is “lifting a cloud” over Alexion, but they still have their concerns:

    Without significant fireworks mgt. has filed the 10-Q lifting a cloud around the details on the potential wrong doing and its impact. While the “pull-in” sales had less than a 1% impact and do not appear pervasive in use as evidenced by the limited amount outside of 4Q15, we do wonder how the increased scrutiny will impact the selling organization and the potential increased conservatism among personnel going forward. We look forward to 2017 guidance and updates to MG filing and 1210 enrollment at the 4Q16 call.

    Alexion’s market capitalization rose to $31.2 billion today from $28.5 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

  • [By Ben Levisohn]

    Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.

    Getty Images

    That would be Alexion, which reported a profit of $1.38, beating forecasts for $1.23, according to Reuters, on sales of $870 million, ahead of analyst expectations for $826.6 million. Those results have sent Alexion shares up 5.1% to $126.87 at 34:35 p.m. today.

    Unfortunately, Amgen and Celgene are trading lower, despite beating earnings forecasts. Credit Suisse analystAlethia Young and team call Amgen’s quarter “mixed,” which helps explain why its stock has dropped 1.4% to $162.25. They explain:

    Product revenues were light by $200M although the company raised their bottom line EPS guidance for 2017. Newer product volume growth seemed sound although some legacy products experienced challenges: Reported revenues were $5.46B vs. consensus of $5.57B. EPS beat with $3.15/sh non-GAAP EPS vs. consensus of $3.00/sh driven by lower OpEx spend, specifically with non-GAAP R&D coming in at $748M vs. $900M consensus. We think results for the quarter were mixed, with some notable headwinds on the topline. After listening to the call, it seems the quarter consisted of various one-type dynamics for products where revenues were light (Enbrel and Repatha). Enbrel missed by close to $200M ($1,181M vs. $1,360M consensus) and we think rheumatology/dermatology dynamics (both pricing and volume) remain a focus for investors. Repatha came in at $50M vs. $72M consensus although the company noted last quarter was helped by a one-time bulk order. Neulasta helped on the topline at $1,210M vs. $1,142M consensus although this was helped by some purchases from larger end customers.

    …while Evercore ISI’s Umer Raffat explains why investors were disappointed by Celgene’s earnings beat:

    Celg

intraday trading: LivaNova PLC(LIVN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggested small cap medical technology stock LivaNova PLC (NASDAQ: LIVN):

    From a fundamental perspective, LIVN currently offers investors with a potentially nice opportunity on both a short and long-term basis. With a $2.37B market cap, this pure mid-cap play currently trades at a forward P/E of just over 14 and a five year PEG of just 1.15. The Company is also projected to grow their bottom line from this year to next by as much as 14%